Skip to main content
SpringerLink
Log in

Gentherapie bei Knorpeldefekten

  • Chapter
Gelenkknorpeldefekte

  • 56 Accesses

Zusammenfassung

Der Einsatz der somatischen Gentherapie eröffnet völlig neue Möglichkeiten bei der Behandlung von Knorpeldefekten. Im Gegensatz zu anderen therapeutischen Ansätzen kann durch die Gentherapie das biologische System, welches zur Destruktion des Knorpels führt, direkt und damit sehr effektiv beeinflusst werden. Durch die gezielte Transfektion der lokalen Knorpelzellen in einem Knorpeldefekt mit einem Gen können Konzentrationen von therapeutisch wirksamen Substanzen erreicht werden, welche bei herkömmlichen Applikationsformen (Injektion, parenterale Gabe) unerreichbar sind. Durch die Produktion einer Substanz vor Ort werden Nachteile der systemischen Gabe, wie z. B. Proteolyse oder Inhibition durch andere Moleküle, umgangen. Die Intensität und die Dauer der Genexpression läßt sich über geeignete Promotorsequenzen, die das Ablesen des Gens steuern, regulieren. Auf diese Weise ist es möglich, therapeutisch wirksame Substanzen über einen definierten Zeitraum lokal und dadurch relativ nebenwirkungsarm bereitzustellen. Reparationsprozesse könnten somit gezielt gesteuert und unterstützt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH (1996) Suppression of antigen-induced arthritis by gene therapy. J Immunol 156:3558–3562

    PubMed  CAS  Google Scholar 

  2. Makarov SS, Olsen JC, Johnson WN, Anderle SK, Brown RR, Baldwin AS, Haskill JS, Schwab JH (1996) Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA. Proc Natl Acad Sci USA 93:402–406

    Article  PubMed  CAS  Google Scholar 

  3. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C (1998) Adenovirus mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 160:5213–5220

    PubMed  CAS  Google Scholar 

  4. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Bar-ranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM (1996) Clinical trial to assess the safety, feasibility and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gen Ther 7:1261–1280

    Article  CAS  Google Scholar 

  5. McCarthy M (1996) Gene therapy for rheumatoid arthritis starts clinical trials. Lancet 348:323

    Article  Google Scholar 

  6. Müller-Ladner U, Evans CH, Franklin BN, Roberts CR, Gay RE, Robbins PD, Gay S (1999) Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 42:490–497

    Article  PubMed  Google Scholar 

  7. Chernajovsky Y, Adams G, Podhajcer O, Mueller G, Robbins PD, Feldman M (1995) Inhibition of transfer of collagen-induced arthritis into SCID mice by gene transfer of spleen cells with retrovirus expressing soluble human tumor necrosis factor receptor. Gene Ther 2:731–735

    PubMed  CAS  Google Scholar 

  8. Moreland LW, Baumgartner SW, Shiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 337:141–147

    Article  CAS  Google Scholar 

  9. Song XY, Gu M, Jin WW, Klinman M, Wahl SM (1998) Plasmid DNA encoding transforming growth factor-betal suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 101:1–7

    Article  Google Scholar 

  10. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledder F, Podhajcer OL (1997) Pathogenic lymphoids cells engineered to express TGF-betal ameliorate disease in a collagen-induced arthritis model. Gene Ther 4:553–559

    Article  PubMed  CAS  Google Scholar 

  11. Malemud CJ, Killeen W, Hering TM, Purchio AF (1991) Enhanced sulfated-proteoglycan core protein synthesis by incubation of rabbit chondrocytes with recombinant transforming growth factor-betal. J Cell Physiol 149:151–159

    Article  Google Scholar 

  12. Malemud CJ, Stevenson S, Mehraban F, Papay RS, Purchio AF, Goldberg VM (1994) The proteoglycan synthesis repertoire of rabbit chondrocytes maintained in Type II collagen gels. Osteoarthritis Cartilage 2:29–42

    Article  PubMed  CAS  Google Scholar 

  13. Möller HD, Evans CH (1999) Therapy of arthritis by gene transfer. Orthopäde 28:76–81

    PubMed  Google Scholar 

  14. Wanner R, Zhang J, Dorbic T, Mischke D, Henz BM, Wittig B, Rosenbach T (1997) The promoter of the HaCaT keratinocyte differentiation-related gene keratin 4 contains a functional AP-2 binding site. Arch Dermatol Res 289:705–708

    Article  PubMed  CAS  Google Scholar 

  15. Sun Y, Jurgovsky K, Möller P, Alijagic D, Dorbic T, Georgieva J, Wittig B, Schadendorf D (1998) Vaccination with IL-12-gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481–490

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Wallich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Vettel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Orthopädische Universitätsklinik, Hugstetter Str. 55, Freiburg, D-79106, Germany

    Christoph Erggelet  & Matthias Steinwachs  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schneider, U., Wallich, R., Vettel, U. (2001). Gentherapie bei Knorpeldefekten. In: Erggelet, C., Steinwachs, M. (eds) Gelenkknorpeldefekte. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57716-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57716-1_5

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-7985-1265-8

  • Online ISBN: 978-3-642-57716-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation